Japan is considering a new approach to its “special” market expansion re-pricing that would exclude drug sales tied to private…
HOME > TOP STORIES
TOP STORIES
-
BUSINESS Novo Nordisk Logs 3.6% Growth in Japan in 2024, Driven by Semaglutide
April 28, 2025
-
BUSINESS Sanofi Looks to Join Top 3 in Japan Pharma Market by 2030
April 25, 2025
-
REGULATORY MOF’s Spring Debate Puts Special Focus on CEA, More Aggressive Re-Pricing Eyed
April 24, 2025
-
REGULATORY Epkinly to Face Price Cuts under CEA Scheme
April 24, 2025
-
BUSINESS Takeda’s Japan Earnings Bottomed Out, Now on Pace to Growth from FY2025: Head
April 23, 2025
-
REGULATORY GSK’s Blenrep, Moderna RSV Jab Edge Closer to Japan Approval with Panel OK
April 22, 2025
-
REGULATORY MOF Tells LDP Members Govt Can Address Inflation with Current Budget Policy
April 21, 2025
-
BUSINESS Investments Follow Where Innovation Is Valued, Says Novartis Japan Chief
April 18, 2025
-
BUSINESS Gilead Shelves Sunlenca’s PrEP Program in Japan as Coverage Issue Weighs
April 17, 2025
-
BUSINESS Gilead Japan Revving Up Oncology Drive with Trodelvy, CAR-T as Legs of Growth
April 17, 2025
-
REGULATORY MHLW to Revise Patent Linkage Scheme in FY2025, Create Expert Committee
April 16, 2025
-
BUSINESS Marubeni Sees Drug Biz Opportunities in Global Markets with Supply-Demand Gaps
April 16, 2025
-
BUSINESS AstraZeneca Eyes 40 Approvals by 2030 in Japan, Driven by New Modalities
April 15, 2025
-
BUSINESS Servier Poised to Double Japan Workforce over Next 3 Years: CEO, Local Chief
April 14, 2025
-
REGULATORY Japan Govt Ends Subsidies for COVID Vaccinations from FY2025
April 14, 2025
-
BUSINESS Japan Biotechs to Be Hit Hard by TSE Growth Market Reform, 26 Firms Fail to Reach Proposed Threshold
April 11, 2025
-
REGULATORY Nippon Ishin Co-Leader Shows Understanding of Off-Year Price Revisions
April 11, 2025
-
REGULATORY Bill to Nix Off-Year Scheme Politicized, Could Clear Lower House with Ishin Support
April 10, 2025
-
REGULATORY Amgen’s Imdelltra, CSL’s Andembry to Join NHI Price List on April 16
April 10, 2025
-
ORGANIZATION No. 1 Priority of Public-Private Council Must Be Drug Pricing: PhRMA Japan Chair
April 9, 2025
ページ
Japan has presented its latest draft policy direction for its FY2026 drug pricing reform. While the package includes a string…
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…